Our top pick for
Acceleron Pharma Inc is a biotechnology business based in the US. Acceleron Pharma shares (XLRN) are listed on the NASDAQ and all prices are listed in US Dollars. Acceleron Pharma employs 312 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$172.94|
|52-week range||$99.98 - $189.99|
|50-day moving average||$147.70|
|200-day moving average||$130.73|
|Wall St. target price||$179.10|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.71|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||-1.18%|
|1 month (2021-09-17)||25.68%|
|3 months (2021-07-17)||47.46%|
|6 months (2021-04-16)||41.70%|
|1 year (2020-10-16)||48.05%|
|2 years (2019-10-17)||299.86%|
|3 years (2018-10-17)||235.09%|
|5 years (2016-10-17)||479.17%|
|Revenue TTM||$101.1 million|
|Gross profit TTM||$-81,394,000|
|Return on assets TTM||-21.29%|
|Return on equity TTM||-37.76%|
|Market capitalisation||$10.7 billion|
TTM: trailing 12 months
There are currently 2.0 million Acceleron Pharma shares held short by investors – that's known as Acceleron Pharma's "short interest". This figure is 4.5% down from 2.1 million last month.
There are a few different ways that this level of interest in shorting Acceleron Pharma shares can be evaluated.
Acceleron Pharma's "short interest ratio" (SIR) is the quantity of Acceleron Pharma shares currently shorted divided by the average quantity of Acceleron Pharma shares traded daily (recently around 198820.86258776). Acceleron Pharma's SIR currently stands at 9.97. In other words for every 100,000 Acceleron Pharma shares traded daily on the market, roughly 9970 shares are currently held short.
However Acceleron Pharma's short interest can also be evaluated against the total number of Acceleron Pharma shares, or, against the total number of tradable Acceleron Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Acceleron Pharma's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Acceleron Pharma shares in existence, roughly 30 shares are currently held short) or 0.0399% of the tradable shares (for every 100,000 tradable Acceleron Pharma shares, roughly 40 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Acceleron Pharma.
Find out more about how you can short Acceleron Pharma stock.
We're not expecting Acceleron Pharma to pay a dividend over the next 12 months.
Over the last 12 months, Acceleron Pharma's shares have ranged in value from as little as $99.98 up to $189.99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acceleron Pharma's is 0.2228. This would suggest that Acceleron Pharma's shares are less volatile than average (for this exchange).
Acceleron Pharma Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia. The company is also developing Sotatercept, an activin receptor type IIA fusion protein, for the treatment of patients with pulmonary arterial hypertension; ACE-1334, a pulmonary therapeutic candidate that is in Phase I clinical trials; and luspatercept-aamt for non-transfusion-dependent beta-thalassemia patients and lower-risk myelodysplastic syndrome patients. It has a license agreements with the Salk Institute for Biological Studies for the cloning of type II activin receptors; and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.